Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 234

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer

Open access
Yu, Jian, Kane, Susan, Wu, Jiong, Benedettini, Elisa, Li, Daiqiang, Reeves, Cynthia, Innocenti, Gregory, Wetzel, Randy, Crosby, Katherine, Becker, Alison, Ferrante, Michelle, Cheung, Wan Cheung, Hong, Xiqiang, Chirieac, Lucian R., Sholl, Lynette M., Haack, Herbert, Smith, Bradley L., Polakiewicz, Roberto D., Tan, Yi, Gu, Ting-Lei, Loda, Massimo, Zhou, Xinmin, Comb, Michael J. · 2009 · Clinical Cancer Research

Abstract

Purpose: Activating mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are found in approximately 10% to 20% of non–small-cell lung cancer (NSCLC) patients and are associated with response to EGFR inhibitors. The most common NSCLC-associated EGFR mutations are deletions in exon 19 and L858R mutation in exon 21, together accounting for 90% of EGFR mutations. To develop a simple, sensitive, and reliable clinical assay for the identification of EGFR mutations in NSCLC patients, we generated mutation-specific rabbit monoclonal antibodies against each of these two most common EGFR mutations and aimed to evaluate the detection of EGFR mutations in NSCLC patients by immunohistochemistry. Experimental Design: We tested mutation-specific antibodies by Western blot, immunofluorescence, and immunohistochemistry. In addition, we stained 40 EGFR genotyped NSCLC tumor samples by immunohistochemistry with these antibodies. Finally, with a panel of four antibodies, we screened a large set of NSCLC patient samples with unknown genotype and confirmed the immunohistochemistry results by DNA sequencing. Results: These two antibodies specifically detect the corresponding mutant form of EGFR by Western blotting, immunofluorescence, and immunohistochemistry. Screening a panel of 340 paraffin-embedded NSCLC tumor samples with these antibodies showed that the sensitivity of the immunohistochemistry assay is 92%, with a specificity of 99% as compared with direct and mass spectrometry–based DNA sequencing. Conclusions: This simple assay for detection of EGFR mutations in diagnostic human tissues provides a rapid, sensitive, specific, and cost-effective method to identify lung cancer patients responsive to EGFR-based therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-08-2739

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 234

Metadata

Authors
Yu, J., Kane, S., Wu, J., Benedettini, E., Li, D., Reeves, C., Innocenti, G., Wetzel, R., Crosby, K., Becker, A., Ferrante, M., Cheung, W. C., Hong, X., Chirieac, L. R., Sholl, L. M., Haack, H., Smith, B. L., Polakiewicz, R. D., Tan, Y., Gu, T.-L., Loda, M., Zhou, X., & Comb, M. J.
Venue
Clinical Cancer Research
Published
2009-04-30
Volume
15
Issue
9
Pages
3023-3028
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2120669034
Cited by
234
References
4
FWCI
21.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-2739
The paper
Yu, J., Kane, S., Wu, J., Benedettini, E., Li, D., Reeves, C., Innocenti, G., Wetzel, R., Crosby, K., Becker, A., Ferrante, M., Cheung, W. C., Hong, X., Chirieac, L. R., Sholl, L. M., Haack, H., Smith, B. L., Polakiewicz, R. D., Tan, Y., . . . Comb, M. J. (2009). Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-2739

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.